Literature DB >> 31372268

The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells.

Jianying Xi1, Liang Wang1, Chong Yan1, Jie Song1, Yang Song2, Ji Chen2, Yongjun Zhu2, Zhiming Chen2, Chun Jin3, Jianyong Ding3, Chongbo Zhao1,4.   

Abstract

BACKGROUND: Myasthenia gravis (MG) is a group of autoimmune disease which could be accompanied by thymoma. Many differences have been observed between thymoma-associated MG (TAMG) and non-MG thymoma (NMG). However, the molecular difference between them remained unknown. This study aimed to explore the differentially expressed genes (DEGs) between the two categories and to elucidate the possible pathogenesis of TAMG further.
METHODS: DEGs were calculated using the RNA-Sequencing data from 11 TAMG and 10 NMG in The Cancer Genome Atlas (TCGA) database. GeneAnalytics was performed to characterize the associations between DEGs and tissues and cells, diseases, gene ontology (GO) terms, pathways, phenotypes, and drug/compounds, respectively. Genes related to T cells were sorted out using LifeMapDiscovery Cells and Tissues Database. Genes directly related to the phenotype of autoimmune diseases that were identified by VarElect were validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
RESULTS: The expression level of 169 genes showed a significant difference between the two groups, with 94 up-regulated and 75 down-regulated. Overexpression of six genes (ATM, SFTPB, ANKRD55, BTLA, CCR7, TNFRSF25), which are expressed in T cells and directly related to autoimmune disease through VarElect, was identified. The overexpression of soluble BTLA (sBTLA) (P=0.027), CCR7 (P=0.0018), TNFRSF25 (P=0.0013) and ANKRD55 (P=0.0026) was validated by RT-qPCR in thymoma tissues from our center.
CONCLUSIONS: Overexpression of sBTLA, CCR7, TNFRSF25 and ANKRD55 was identified and validated by RT-qPCR, which could partly explain the underlying pathogenesis in TAMG.

Entities:  

Keywords:  ANKRD55; CCR7; TNFRSF25; Thymoma; differentially expressed genes (DEGs); myasthenia gravis (MG); soluble BTLA

Year:  2019        PMID: 31372268      PMCID: PMC6626793          DOI: 10.21037/jtd.2019.06.01

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  47 in total

Review 1.  Thymoma: state of the art.

Authors:  C R Thomas; C D Wright; P J Loehrer
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

Review 2.  Ankyrin repeat: a unique motif mediating protein-protein interactions.

Authors:  Junan Li; Anjali Mahajan; Ming-Daw Tsai
Journal:  Biochemistry       Date:  2006-12-26       Impact factor: 3.162

Review 3.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Authors:  A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

4.  B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.

Authors:  John R Sedy; Maya Gavrieli; Karen G Potter; Michelle A Hurchla; R Coleman Lindsley; Kai Hildner; Stefanie Scheu; Klaus Pfeffer; Carl F Ware; Theresa L Murphy; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2004-11-28       Impact factor: 25.606

5.  Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS.

Authors:  Z Lin; C Pearson; V Chinchilli; S M Pietschmann; J Luo; U Pison; J Floros
Journal:  Clin Genet       Date:  2000-09       Impact factor: 4.438

6.  Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population.

Authors:  X Guo; H M Lin; Z Lin; M Montaño; R Sansores; G Wang; S DiAngelo; A Pardo; M Selman; J Floros
Journal:  Eur Respir J       Date:  2001-09       Impact factor: 16.671

Review 7.  Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis.

Authors:  Meinoshin Okumura; Yoshitaka Fujii; Hiroyuki Shiono; Masayoshi Inoue; Masato Minami; Tomoki Utsumi; Yoshihisa Kadota; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-04-10

8.  An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection.

Authors:  Peggy Han; Olivia D Goularte; Kevin Rufner; Beverley Wilkinson; Jonathan Kaye
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

9.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.

Authors:  Norihiko Watanabe; Maya Gavrieli; John R Sedy; Jianfei Yang; Francesca Fallarino; Susan K Loftin; Michelle A Hurchla; Natalie Zimmerman; Julia Sim; Xingxing Zang; Theresa L Murphy; John H Russell; James P Allison; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2003-06-08       Impact factor: 25.606

10.  The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases.

Authors:  Françoise Meylan; Todd S Davidson; Erin Kahle; Michelle Kinder; Krishika Acharya; Dragana Jankovic; Virgilio Bundoc; Marcus Hodges; Ethan M Shevach; Andrea Keane-Myers; Eddie C Y Wang; Richard M Siegel
Journal:  Immunity       Date:  2008-06-19       Impact factor: 31.745

View more
  3 in total

1.  DCAF12 and HSPA1A May Serve as Potential Diagnostic Biomarkers for Myasthenia Gravis.

Authors:  Weidong Nong; Fang Huang; Fengping Mao; Dayuan Lao; Zhuowei Gong; Wen Huang
Journal:  Biomed Res Int       Date:  2022-05-24       Impact factor: 3.246

2.  Identification of Molecular Characteristics and New Prognostic Targets for Thymoma by Multiomics Analysis.

Authors:  Dazhong Liu; Pengfei Zhang; Jiaying Zhao; Lei Yang; Wei Wang
Journal:  Biomed Res Int       Date:  2021-05-19       Impact factor: 3.411

3.  Investigation of BTLA tagging variants with risk of esophagogastric junction adenocarcinoma.

Authors:  Weifeng Tang; Shuchen Chen; Mingqiang Kang; Jun Liu; Chao Liu
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.